Publicaciones
-
Baulenas-Farrés M, Paco-Mercader S, Marino F, Mohr J, Panisello C, Balaguer-Lluna L, Aschero MR, Cuadrado-Vilanova M, Resa-Parés C, Rodriguez E, Márquez-Pereira JM, Menéndez P, Jou-Munoz C, Benítez R, Benitez-Ribas D, Lavarino C, Mora J and Carcaboso AM.
Proteins of the cancer cell secretome induce the protumoral microenvironment of diffuse intrinsic pontine glioma
neuro-oncology advances . 7(1): .
-
Krauel L, Pasten A, Gorostegui M, Mañé S, Martin Giménez MP, Coronas-Soucheiron M, Carrasco-Torrents R and Mora J.
Use of Radioguided Surgery for Small and Difficult-to-Locate Relapsed MIBG (+) High-Risk Neuroblastoma Lesions
Cancers . 16(19): . Nº de citas: 1
-
Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J.
Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes
PEDIATRIC BLOOD & CANCER . 71(10): .
-
Mahnoor S, Molnar C, Velázquez D, Reina J, Llamazares S, Heinen JP, Mora J and Gonzalez C.
Human EWS-FLI protein levels and neomorphic functions show a complex, function-specific dose-response relationship in Drosophila
OPEN BIOLOGY . 14(7): 240043-240043. Nº de citas: 1
-
Sanchez-Guixe E, Muiños F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, Lavarino C, González- Pérez A, Mora J and López-Bigas N.
Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues
CANCER DISCOVERY . 14(6): 953-964. Nº de citas: 7
-
Caballero R, Pasten A, Giménez C, Raquel Rodriguez Baladon, Carmona-Jiménez RM, Mora J, Valls-Esteve A, Lustig P, Lombardini F, Balsells S and Krauel L.
Beyond Needles: Pioneering Pediatric Care with Virtual Reality (VR) for TIVAD Access in Oncology
Cancers . 16(12): . Nº de citas: 2
-
Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.
Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects
Frontiers in oncology . 14: 1380917-1380917.
-
Pasten A, Salvador-Alarcon C, Mora J, Martín Gimenez MP, Carrasco-Torrents R and Krauel L.
Current Status of Fertility Preservation in Pediatric Oncology Patients
CHILDREN-BASEL . 11(5): . Nº de citas: 4
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Nº de citas: 1
-
Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM.
GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma
INTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Nº de citas: 11